Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

In this Psychiatry Research journal article, the highlights/abstract reads:

Highlights

  • •Independent participant data from psilocybin trials for depression were meta-analyzed.
  • •Psilocybin condition was associated with less symptom worsening relative to waitlist.
  • •There was no difference in symptom worsening between psilocybin and escitalopram.

Abstract

We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using data from the two trials with control arms, the psilocybin arm showed a lower likelihood of symptom worsening versus waitlist, and no difference in the likelihood of symptom worsening versus escitalopram. The limitation of a relatively small sample size should be addressed in future studies.

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Randomized trial of ketamine masked by surgical anesthesia in patients with depression

Next
Next

Roland Griffiths Is dead at 77; Led a renaissance in psychedelics research